Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 8/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.50 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14691030 | 0.98 | ITGB3 (0.50) | ITGB3ITGA2BSLC6A2SLC6A4HRH1 | |
| SCHEMBL12735820 | 0.91 | ITGB3 (0.57) | ITGB3ITGA2BSLC6A2SLC6A4HRH1 | |
| SCHEMBL15281969 | 0.90 | SLC6A2 (0.50) | ITGB3ITGA2BSLC6A2SLC6A4HRH1 | |
| Trifluoroacetic Acid SCHEMBL4327966 | 0.88 | ITGB3 (0.55) | ITGB3ITGA2BTEAD1TEAD3 | |
| SCHEMBL7331063 | 0.88 | HRH1 (0.60) | ITGB3ITGA2BHRH1GBA1 | |
| SCHEMBL3356533 | 0.88 | MAOB (0.53) | ITGB3ITGA2BSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4980425 | 0.87 | TEAD1 (0.56) | TEAD1TEAD3NFE2L2 | |
| Hydrochloric Acid SCHEMBL7334941 | 0.86 | MAOB (0.52) | ITGB3ITGA2BSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL7323876 | 0.86 | HRH1 (0.58) | ITGB3ITGA2BHRH1GBA1 | |
| SCHEMBL15651091 | 0.83 | NFE2L2 (0.71) | ITGB3ITGA2BSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867207-A1 | PHENOXYETHYL PIPERIDINE COMPOUNDS | Eli Lilly and Company (US) | 2015-05-06 | — | — | EP | disclosed |
| EP-2607362-B1 | Piperidine and piperazine carboxylates as FAAH inhibitors | ASTELLAS PHARMA INC (JP) | 2014-12-31 | — | — | EP | disclosed |
| WO-2014004229-A1 | PHENOXYETHYL PIPERIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2014-01-03 | — | — | WO | disclosed |
| EP-1849773-B1 | Piperazine derivatives for the treatment of urinary incontinence and pain | ASTELLAS PHARMA INC (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2607362-A1 | Piperidine and piperazine carboxylates as FAAH inhibitors | Astellas Pharma Inc. (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| US-6780868-B2 | TREATMENT OF MYOCARDIAL OR PERIPHERAL ISCHAEMIA, CARDIAC INSUFFICIENCY OR PULMONARY ARTERIAL HYPERTENSION | LES LABORATOIRES SERVIER (FR) | 2004-08-24 | — | — | US | disclosed |
| US-20030229100-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-12-11 | — | — | US | disclosed |
| US-20030225105-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030191132-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-10-09 | — | — | US | disclosed |
| US-6566364-B2 | Isomers, hydrates, solvates and addition salts in treatment of endothelial dysfunction disease such as atherosclerosis, dyslipidaemia; antidiabetic agents; heart transplantation; inhibition of nitrogen monoxide synthase and oxidative stress | LES LABORATOIRES SERVIER (FR) | 2003-05-20 | — | — | US | disclosed |
| EP-1266896-A1 | Linear ou cyclic ureas, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-12-18 | — | — | EP | disclosed |
| US-6303593-B1 | FOR THERAPY HUMAN IMMUNODEFICIENCY VIRUS INFECTION, AQUIRED IMMUNODEFICIENCY SYNDROME (AIDS), INFLAMMATORY AND IMMUNOREGULATORY DISORDER OR DISEASE, ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS | MERCK & CO., INC. | 2001-10-16 | — | — | US | disclosed |
| US-20010009911-A1 | New linear or cyclic ureas | LES LABORATOIRES SERVIER (FR) | 2001-07-26 | — | — | US | disclosed |
| EP-1113014-A1 | Linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000051608-A1 | 3-THIENYL AND 3-FURANYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009911-A1 | New linear or cyclic ureas | GUCY1B1, UACA, LIPG | ITGB3 2620/4885ITGA2B 2984/4885SLC6A2 2924/4885 |
| US-20030191132-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | ITGB3 2969/4885ITGA2B 3008/4885SLC6A2 3299/4885 |
| US-20030229100-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | ITGB3 2969/4885ITGA2B 3008/4885SLC6A2 3299/4885 |
| US-20030225105-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | ITGB3 2969/4885ITGA2B 3008/4885SLC6A2 3299/4885 |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | ITGB3 639/4885ITGA2B 694/4885SLC6A2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.